New Long-Acting HIV Prevention Option Now Available
A new injectable form of pre-exposure prophylaxis (PrEP) for HIV is now available, offering a convenient alternative to daily oral medication. The treatment, known as APRETUDE (cabotegravir), is approved for at-risk adults and adolescents weighing at least 77 pounds.
APRETUDE is the first injectable PrEP option, and its availability marks a significant step forward in HIV prevention strategies. This new method could improve adherence to PrEP, a crucial factor in its effectiveness, and potentially reduce new HIV infections.
The medication is administered as an injection, providing long-acting protection against HIV-1. According to information available, APRETUDE became reimbursable in France starting March 2, 2026.
Some sources suggest that this injectable option may be more effective than traditional oral PrEP. One association noted that the injectable form is “more performant than an oral treatment.”
More information about APRETUDE, including prescribing information and a boxed warning, can be found at the official website. Frequently asked questions are also available here.
